Moberg Pharma is carrying out clinical trials in several disease areas. A phase II trial for nail fungus is currently ongoing.
Ongoing clinical trials
The
decision to initiate a phase II study for a new formulation of MOB-015 has been
taken. The first of a total of 35 patients will be included
in December 2012 in the Sahlgenska University Hospital (Gothenburg
area).
Doctors and researchers are encouraged to get in touch regarding interest in participation in clinical trials, ideas for improved products and matters in connection with our existing products and projects. Please contact Kjell Rensfeldt, VP Research and Development, Chief Medical Officer, at
kjell.rensfeldt@mobergpharma.se.
Moberg Pharma’s work has a major impact on peoples’ life and
health and therefore it is imperative that the company not only
complies with applicable laws and regulations, but also acts in a
responsible and ethical manner. Preclinical and clinical trials on
the company’s pharmaceutical candidates are conducted in collaboration
with partners, for example contract research companies
or research teams associated with universities.
Clinical trials must always be set up in consultation between
Moberg Pharma and the respective partner, and be approved by
Moberg Pharma. Clinical trials are conducted in accordance with
Good Clinical Practice (GCP) and are carried out in collaboration
with specialized contract research companies. Implementation
is regulated by special processes, known as Standard Operating
Procedures, as well as quality contracts, to ensure that Moberg Pharma’s clinical trials are always conducted according to standard
practice and that laws and regulations are followed.